bevacizumab/nab-paclitaxel (AB160) / Sorrento, Mayo Clinic - LARVOL DELTA

Bevacizumab plus nab-paclitaxel and platinum as second-line therapy for driver-gene-negative non-squamous non-small cell lung cancer after immunochemotherapy: A prospective single-arm single-centre study. (PubMed, Clin Transl Med) - "The BAP regimen demonstrated preliminary efficacy with manageable safety as a second-line therapy for patients with advanced driver-gene-negative nsqNSCLC after immunochemotherapy. Plasma TWEAK levels may serve as a potential biomarker to help identify patients who might benefit most from this sequential treatment modality, pending further independent validation. Further studies are needed."

Journal • Lung Cancer • Lung Non-Squamous Non-Small Cell Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • TNFSF12

Bevacizumab Plus Nab-paclitaxel and Tegafur Gimeracil Oteracil Potassium Capsule (S-1) as Second-line Treatment for Advanced Biliary Tract Cancer: a Phase ? Clinical Trial (clinicaltrials.gov) - P2 | N=32 | Completed | Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

New P2 trial • Biliary Cancer • Biliary Tract Cancer • Oncology • Solid Tumor

Safety and efficacy of nab-paclitaxel combined with nedaplatin and bevacizumab in patients with platinum-resistant epithelial ovarian cancer: a retrospective cohort study. (PubMed, J Cancer Res Clin Oncol) - "This chemotherapy regimen demonstrated satisfactory therapeutic efficacy and manageable toxicity in heavily pretreated PROC, suggesting its potential as a viable treatment alternative."

Journal • Platinum resistant • Retrospective data • Epithelial Ovarian Cancer • Hematological Disorders • Oncology • Ovarian Cancer • Solid Tumor

IBI363 Plus Bevacizumab With or Without Nab-Paclitaxel for Second-Line Treatment of Advanced Gastric Cancer (clinicaltrials.gov) - P1/2 | N=50 | Not yet recruiting | Sponsor: The First Affiliated Hospital of Zhengzhou University

New P1/2 trial • Gastric Cancer • Gastroesophageal Junction Adenocarcinoma • Oncology • Solid Tumor

A Phase I trial of Nab-Paclitaxel/Bevacizumab (AB160) Nano-Immunoconjugate Therapy for Gynecologic Malignancies. (PubMed, Clin Cancer Res) - "The safety profile and clinical activity of AB160 supports further clinical testing in patients with gynecologic cancers; the RP2D is DL2 (ABX 150 mg/m2, BEV 60 mg/m2)."

Journal • P1 data • Cardiovascular • Colorectal Cancer • Gynecologic Cancers • Hematological Disorders • Leukopenia • Neutropenia • Oncology • Ovarian Cancer • Solid Tumor

NALIRIFOX, FOLFIRINOX or Gemcitabine Nab-Paclitaxel in Advanced PDAC: Who is a Candidate? (Mayo Clinic School of Continuous Professional Development)

CME

A phase I trial of Nab-Paclitaxel/Bevacizumab (AB160) nano-immunoconjugate therapy for metastatic gynecological malignancies: MC1371 (NCT02020707) (SGO 2023) - P1 | No abstract available

Metastases • P1 data • Gynecologic Cancers • Oncology

ASCO GI 2023 NAPOLI-3 Randomized, Open-Label Phase 3 Study: Liposomal Irinotecan + 5-Fluorouracil/Leucovorin + Oxaliplatin (NALIRIFOX) vs. nab-Paclitaxel + Gemcitabine in Treatment-Naïve Patients With mPDAC (VuMedi) - https://www.vumedi.com/video/asco-gi-2023-napoli-3-randomized-open-label-phase-3-study-liposomal-irinotecan-5-fluorouracilleucovo/

Video

daNIS-2: NIS793 with nab-paclitaxel and gemcitabine in mPDAC (YouTube) - "Zev Wainberg, MD...discusses patient reported outcomes and biomarkers in the Phase III daNIS-2 trial (NCT04935359) of NIS793, an anti-TGF-β monoclonal antibody, in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC). Patients with treatment-naïve mPDAC were recruited and were either given NIS793 with nab-paclitaxel and gemcitabine (NG), or with NG alone. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Gastrointestinal Cancers (GI) Symposium in San Francisco, CA."

Interview • Video

NAPOLI-3: first-line NALIRIFOX in metastatic pancreatic ductal adenocarcinoma (YouTube) - "Zev Wainberg, MD...presents findings from the Phase III NAPOLI-3 trial (NCT04083235), which compared liposomal irinotecan, oxaliplatin, 5-fluorouracil, and leucovorin (NALIRIFOX) to nab-paclitaxel with gemcitabine in previously untreated patients with metastatic pancreatic ductal adenocarcinoma. Patients receiving NALIRIFOX demonstrated superior overall survival and progression-free survival, providing a promising first-line treatment for a group of patients with limited options. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Gastrointestinal Cancers (GI) Symposium in San Francisco, CA."

Interview • Video

Nab-paclitaxel does not extend biliary tract cancer survival, but may benefit some (Eurekalert) - "Adding nab-paclitaxel to a standard treatment of gemcitabine plus cisplatin does not significantly extend median overall survival (OS) time for patients with advanced biliary tract cancers, although it may provide a benefit for subsets of patients with locally advanced disease or gallbladder adenocarcinoma....authors on the abstract include...Howard S. Hochster, MD..."

Checkpoint inhibition in hepatocellular carcinoma (YouTube) - "Ghassan Abou-Alfa, MD, MBA...provides an overview of immune checkpoint inhibitors (ICIs) in treating hepatocellular carcinoma. Current double therapies incorporating ICIs including durvalumab and tremelimumab as well as atezolizumab and bevacizumab have been assessed in clinical trials such as the Phase III IMbrave150 trial (NCT03434379) of the latter combination against sorafenib. Prof. Abou-Alfa additionally highlights data from a real world study which shows patients with hepatitis B are especially more likely to benefit from checkpoint inhibition. This interview took place virtually at the 2022 Great Debates & Updates in Gastrointestinal Malignancies Congress."

Video

Plasma Growth Hormone in HCC: A Biomarker of Response to Atezo/Bev? (Oncotarget) - "Atezolizumab and bevacizumab are two standard therapies used to treat unresectable, advanced HCC. However, researchers...Ahmed Omar Kaseb...noticed a significant gap in research on biomarkers of response in advanced HCC patients treated with atezolizumab plus bevacizumab. The team conducted a new study aimed at beginning to close this gap....'This study investigated the biomarker value of plasma growth hormone (GH) level as a potential biomarker to predict outcome in unresectable HCC patients treated with current standard therapy, atezolizumab plus bevacizumab (Atezo/Bev).'"

Audio